Avalo Therapeutics Announces Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)

Core Insights - Avalo Therapeutics, Inc. announced the grant of inducement equity awards to three new employees, totaling 114,000 nonstatutory stock options [1][2] Group 1: Inducement Equity Awards - The options were granted on November 4, November 10, and November 17, 2025, with recipients entitled to purchase 24,000, 72,000, and 18,000 shares of common stock respectively [2] - The exercise price for the options is set at the closing price on the respective grant dates, and the options will vest over four years [2] - Vesting schedule includes 25% of shares vesting on the one-year anniversary of each employee's start date, with the remaining shares vesting monthly over the following 36 months [2] Group 2: Company Overview - Avalo Therapeutics is focused on developing IL-1β-based treatments for immune-mediated inflammatory diseases, with its lead asset AVTX-009 currently in a Phase 2 clinical trial for hidradenitis suppurativa [3] - The company is exploring additional opportunities in prevalent indications with significant unmet needs [3] Group 3: Product Information - AVTX-009 is a humanized monoclonal antibody that binds to interleukin-1β (IL-1β) and neutralizes its activity, playing a central role in the pathogenesis of various human diseases [4] - Dysregulated IL-1β signaling is a major driver of inflammation, and its inhibition has shown effectiveness in multiple immune-mediated inflammatory diseases [4]